Mangoceuticals (NASDAQ:MGRX – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a report on Monday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Mangoceuticals currently has an average rating of “Sell”.
Get Our Latest Stock Report on Mangoceuticals
Mangoceuticals Stock Down 1.8%
Mangoceuticals (NASDAQ:MGRX – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.69) earnings per share for the quarter. Mangoceuticals had a negative return on equity of 114.63% and a negative net margin of 4,253.43%.The company had revenue of $0.08 million for the quarter.
Institutional Investors Weigh In On Mangoceuticals
An institutional investor recently raised its position in Mangoceuticals stock. Geode Capital Management LLC boosted its stake in Mangoceuticals, Inc. (NASDAQ:MGRX – Free Report) by 35.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,498 shares of the company’s stock after buying an additional 6,928 shares during the period. Geode Capital Management LLC owned 0.51% of Mangoceuticals worth $40,000 at the end of the most recent quarter. 56.72% of the stock is currently owned by institutional investors.
Mangoceuticals Company Profile
Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.
Featured Stories
- Five stocks we like better than Mangoceuticals
- ESG Stocks, What Investors Should Know
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- The Significance of Brokerage Rankings in Stock Selection
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- Most active stocks: Dollar volume vs share volume
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
